These are the abdomen and the thigh
Based on the mechanism of each component, the patients most likely to benefit from exploring KLOW with their physician are those who: Are actively on a GLP-1 receptor agonist (semaglutide, tirzepatide, retatrutide) and losing weight at a rate of 12+ lb/week Are experiencing visible skin laxity, facial volume loss, or skin texture changes as weight declines Have significant GI side effects (nausea, diarrhoea, mucosal discomfort) during dose escalation Carry known markers of systemic inflammation elevated hsCRP, elevated fasting insulin, or other metabolic biomarkers that have been flagged in prior lab work Are in their 40s or older, where baseline collagen decline makes the gap between demand and capacity most acute Have a history of inflammatory bowel conditions, slow wound healing, or joint/soft tissue injuries that have not fully resolved KLOW is less likely to be the primary tool for patients who are early in GLP-1 therapy, losing weight slowly, have no skin or GI symptoms, and carry no background inflammatory burden
Weve then assumed that 30% of these people will ultimately end up on GLP-1 receptor agonist drugs, or 3.3m people, which is around 5% of the overall population
We were looking for a way to actually increase carnitine levels where it matters mostinside muscle tissue
For MI, curcumin can inhibit NLRP3 inflammasomes by reducing oxidative stress, mitochondrial dysfunction and reactive oxygen species (ROS), and inhibits CRP production in aldosterone-induced rat vascular smooth muscle cells through the ROS-ERK1/2 signaling pathway
